Cargando…
Glutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrum disorder (ASD) – study protocol for a randomised controlled trial
BACKGROUND: Compulsivity is a cross-disorder trait underlying phenotypically distinct psychiatric disorders that emerge in childhood or adolescence. Despite the effectiveness of serotonergic compounds in the treatment of obsessive-compulsive disorder, treatment-resistant symptoms remaining in 40 to...
Autores principales: | Häge, Alexander, Banaschewski, Tobias, Buitelaar, Jan K., Dijkhuizen, Rick M., Franke, Barbara, Lythgoe, David J., Mechler, Konstantin, Williams, Steven C. R., Dittmann, Ralf W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4794817/ https://www.ncbi.nlm.nih.gov/pubmed/26983548 http://dx.doi.org/10.1186/s13063-016-1266-8 |
Ejemplares similares
-
Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD)
por: Del Casale, Antonio, et al.
Publicado: (2019) -
Impact of COVID-19 on Obsessive Compulsive Disorder (OCD)
por: Chakraborty, Abhijit, et al.
Publicado: (2020) -
Glutamatergic Synaptic Dysfunction and Obsessive-Compulsive Disorder
por: Ting, Jonathan T, et al.
Publicado: (2008) -
Glutamatergic augmentation strategies in obsessive–compulsive disorder
por: Sheshachala, Karthik, et al.
Publicado: (2019) -
The Role of N-Acetylcysteine in Obsessive-Compulsive (OCD) and Related Disorders
por: Sá Couto, J., et al.
Publicado: (2022)